JCR’s GVHD 1.5 Years Ahead Of Schedule, Application Planned For 2014
This article was originally published in PharmAsia News
JCR Pharmaceuticals announced Nov. 19 they reached the target number of cases for domestic Phase II/III trials for JR-031, a drug the company is developing for the treatment of graft-versus-host disease, a serious complication that occurs during hematopoietic stem cell and bone marrow transplantation.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.